Skip to main content

Table 2 Cell growth characteristics, IC 50 values and mutation status of ovarian cancer cell lines derived either at initial diagnosis (TOV1369, OV2295, TOV3133G, TOV3133D), or relapse after chemotherapy (OV1369(R2), OV2295(R2), TOV2295(R), OV3133(R), OV3133(R2))

From: Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer

  

TOV1369

OV1369 (R2)

OV2295

OV2295 (R2)

TOV2295 (R)

TOV3133G

TOV3133D

OV3133 (R)

OV3133 (R2)

TOV112D

TOV1946

Cell growth characteristic

Doubling time (avg ± SD)

2.87 ± 0.03

2.45 ± 0.12

2.90 ± 0.10

2.73 ± 0.12

2.49 ± 0.49

2.70 ± 0.15

2.63 ± 0.11

2.94 ± 0.07

3.23 ± 0.12

1.49

2.2 ± 0.26

 

Saturation densisty 1 (x106 cells) (avg ± SD)

2.37 ± 0.19

3.52 ± 0.12

1.52 ± 0.25

1.63 ± 0.12

1.46 ± 0.07

3.11 ± 0.05

3.14 ± 0.12

2.25 ± 0.25

1.34 ± 0.05

10.64

5.66 ± 0.96

 

Number of passages to date

>100

>100

>100

120

>100

>100

84

>100

>100

>100

>100

Spheroid formation

no

aggregate

semi- compact

semi- compact

aggregate

semi- compact

semi- compact

no

aggregate

compact

aggregate

Migration times for wound healing (h)

>48

>48

>48

>48

>48

>48

>48

>48

>48

N/D

24

Soft agarose (colony count) 1 Efficiency (avg ± SD)

>0.1

8.9 ± 5.7

>.0.1

0.2 ± 0.1

0.1 ± 0.1

>0.1

5.0 ± 2.7

>0.1

6.8 ± 3.2

4.7 ± 1.4

4.7 ± 1.9

Subcutaneous injection

Number of mice with tumors

0/6

0/5

0/6

0/6

0/6

0/6

0/6

4/6

0/6

3/3

3/3

 

Mean time of tumor appearance (days) 2

N/A

N/A

N/A

N/A

N/A

N/A

N/A

55 ± 11

N/A

>10

17 ± 4

IC50 3

Carboplatin (μM) (avg ± SD)

5.64 ± 1.29

8.91 ± 5.00

0.05 ± 0.01

0.84 ± 0.25

0.93 ± 0.06

0.75 ± 0.63

1.75 ± 0.88

1.34 ± 0.37

2.65

13.96

4.04 ± 4.19

 

Paclitaxel (nM) (avg ± SD)

22.8 ± 10.7

9.1 ± 6.9

5.4 ± 4.7

2.0 ± 1.5

1.9 ± 0.3

3.5 ± 0.9

2.8 ± 0.3

5.5 ± 3.2

1.6

1.9

3.5 ± 1.8

Mutation

TP53

c.730 G > T (Gly244Cys)

c.730 G > T (Gly244Cys)

c.584 T > C (Ile195Thr)

c.584 T > C (Ile195Thr)

c.584 T > C (Ile195Thr)

c.574C > T (Gln192TE)

c.574C > T (Gln192TE)

c.574C > T (Gln192TE)

c.574C > T (Gln192TE)

c.524 G > A 4 (Arg175His)

c.817C > T 4 (Arg273Cys)

  1. 1Calculated from two independent experiments (in triplicate);
  2. 2Time to tumor appearance is based on the average of the 4 mice for OV3133(R) that developed tumors, with the tumor mass being greater than 200 mm3;
  3. 3Calculated from three independent experiment except for TOV112D and OV3133(R2), which represent triplicate of a single experiment;
  4. 4Mutation for TP53 previously reported in Ouellet et al., 2008 [19].
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us